This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Freeline Therapeutics Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Freeline Therapeutics Holdings kazanç ve gelirinin sırasıyla yıllık 22.5% ve 60.3% oranında artması tahmin edilirken, EPS'nin yıllık 69.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

22.5%

Kazanç büyüme oranı

69.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	36.5%
Gelir büyüme oranı	60.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	01 Aug 2023

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:78F0 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	26	-46	-43	-28	3
12/31/2024	N/A	-76	-72	-69	4
12/31/2023	5	-55	-53	-62	4
3/31/2023	N/A	-61	-77	-70	N/A
12/31/2022	N/A	-89	-85	-78	N/A
9/30/2022	N/A	-101	-79	-76	N/A
6/30/2022	N/A	-117	-86	-83	N/A
3/31/2022	N/A	-132	-102	-100	N/A
12/31/2021	N/A	-140	-112	-108	N/A
9/30/2021	N/A	-144	-129	-124	N/A
6/30/2021	N/A	-138	-136	-132	N/A
3/31/2021	N/A	-115	-115	-111	N/A
12/31/2020	N/A	-96	-97	-95	N/A
9/30/2020	N/A	-73	-73	-72	N/A
6/30/2020	N/A	-63	-53	-51	N/A
3/31/2020	N/A	-58	-57	-54	N/A
12/31/2019	N/A	-54	-55	-52	N/A
12/31/2018	N/A	-33	-30	-26	N/A
9/30/2017	N/A	-17	-20	-19	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 78F0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 78F0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 78F0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 78F0 şirketinin gelirinin (yıllık 60.3% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 78F0 şirketinin gelirinin (yıllık 60.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 78F0 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

This company listing is no longer active

Freeline Therapeutics Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin